Skip to main content
OpenTrials
Completed

NCT Number: NCT02892058

Self-assessment of Flare in Osteoarthritis of Lower Limbs

The need for a tool to measure flare in lower limb osteoarthritis (OA of the hip and knee) is justified by the opportunities for development of clinical trials targeting hip and knee OA long-term treatment (slow acting drug, disease modifying drug) and short-term treatment of symptoms. Such treatments are currently under development and will likely bring important changes in the treatment of patients. The development of a Flare-OA tool would be essential to capture the occurrence of flare, and to implement and adapt treatment strategies.

This project was elaborated with the aims to:

1. define the construct through development of a conceptual framework 2. use the conceptual framework to inform the development of a patient-reported outcome measure, Flare-OA tool, for people with OA 3. evaluate the psychometric properties of the new measure using the OMERACT (Outcome Measures in Rheumatology) filter 2.0 and Rasch measurement methods.

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Institute of Bone and Joint Research - University of Sydney, Sydney, Australia

Loading trial locations.

About this study

Chronologically, the development of a Flare-OA (osteoarthritis) tool will be addressed in the first part of the project (Part 1) and its psychometric validity was evaluated in the second part (Part 2).

Part 1 of the project: The development of the Flare-OA tool will be conducted in several steps, and needs multiple proficiencies in qualitative research (health psychologist), in quantitative research (epidemiologist, psychometrician), in experience of the disease (patients), and in experience of care of the disease (health care professionals).

Two approaches will be taken to define the construct of a flare in lower limb OA: A review of the literature, and the development of a conceptual framework informed by the results of the literature. To help define/conceptualize the construct "Flare in OA" a procedure will be implemented to identify (what are the key variables, or symptoms, that get worse) and clarify (how exactly these variables are described in the literature, by patients, and by clinicians.

Participants :

  • - Patients should be representative of the disease spectrum, i.e. of prevalent cases. They will be recruited in clinical settings and epidemiological sources.
  • - Health care professionals (HCP) will include General Practitioners, Rheumatologists, Rehabilitation specialists, Orthopaedic surgeons, Nurse in general practice or orthopedic wards, Physiotherapists.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • with clinical and radiological hip or knee OA confirmed by a physician,
  • whatever their status regarding flare of OA. The intention of the Flare-OA tool is not to detect current flare only, but also a flare that may have occurred before the encounter with the health care professional. Therefore patient will not be selected on flare, and patients with flare will not be excluded.

Exclusion criteria

  • Patients who never experienced nor currently report having a flare of OA
  • Patients with both hip and knee OA

Treatment and study plan

Primary outcomes

  1. Ability of a FLARE-OA self-questionnaire to detect flare episodes in knee or hip osteoarthritis

    Time frame: Baseline

    patient-reported outcome questionnaire for the self-assessment of flare in osteoarthritis. The questionnaire will be developed during the first part of the study.

  2. Change in ability of a FLARE-OA self-questionnaire to detect flare episodes in knee or hip osteoarthritis during a 6 months period

    Time frame: At 3 and 6 month follow-up

    patient-reported outcome questionnaire for the self-assessment of flare in osteoarthritis. The questionnaire will be developed during the first part of the study.

Secondary outcomes

  1. Evolution of the quality of life during a 6 months period with the standardized OAKHQOL questionnaire

    Time frame: up to 3 and 6 month

    Osteoarthritis knee and hip quality of life questionnaire (OAKHQOL) self-assessment questionnaire

  2. Evolution of the functional limitation related to knee osteoarthritis during a 6 months period with the standardized KOOS questionnaire

    Time frame: up to 3 and 6 month

    Knee injury and Osteoarthritis Outcome Score (KOOS) patient questionnaire. Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4.

  3. Evolution of the functional limitation related to hip osteoarthritis during a 6 months period with the standardized HOOS questionnaire

    Time frame: up to 3 and 6 month

    Hip disability and Osteoarthritis Outcome Score (HOOS) patient questionnaire. Standardized answer options are given (5 Likert boxes) and each question gets a score from 0 to 4.

  4. Pain intensity measure

    Time frame: up to 3 and 6 month

    Self-reported pain intensity using a numerical rating scale

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Official study title

Development of a Tool for the Self-assessment of Flare in Patients With Osteoarthritis of Lower Limbs

Acronym: FLARE-OA

Important dates

Study start
2015
Primary completion
2022
Study completion
2022
First posted
Sep 8, 2016
Registry last updated
Feb 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.